[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546825":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":152,"collaborators":44,"id":154,"slug":44,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":44,"eligibilityCriteria":159,"healthyVolunteers":155,"sex":160,"minAge":161,"maxAge":44,"enrollmentInfo":162,"targetDuration":44,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":44,"overallStatus":49,"whyStopped":44,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"Bracco Diagnostics, Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bolus administration","ACTIVE_COMPARATOR","Bolus administration of 2 mL undiluted Lumason®",[13],"Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]",{"label":15,"type":16,"description":17,"interventionNames":18},"Continuous infusion","EXPERIMENTAL","Continuous infusion of 8 mL of diluted Lumason®",[19],"Drug: Lumason",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]","Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds",[9],[27],"Bolus Administration",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Lumason","Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL\u002Fmin",[15],[33],"Infusion Administration",[35],{"name":36,"affiliation":37,"role":38},"Jose Banchs, MD","Sr. Medical Director","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Rushil Sankpal","CONTACT","609-514-2267",null,"rushil.sankpal@diag.bracco.com",[47,68,85,104,125,136],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Interventional Cardiology Medical Group","RECRUITING","West Hills","California","91307","United States",{"type":55,"coordinates":56},"Point",[57,58],-118.64398,34.19731,{"lat":58,"lon":57},[61,65],{"name":62,"role":42,"phone":63,"phoneExt":44,"email":64},"Michael Fam, MD","818-743-0666","mfam@elegantrd.com",{"name":66,"role":67,"phone":44,"phoneExt":44,"email":44},"Farhad Rafii, MD","PRINCIPAL_INVESTIGATOR",{"facility":69,"status":49,"city":70,"state":71,"zip":72,"country":53,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Piedmont Heart Institute","Atlanta","Georgia","30309",{"type":55,"coordinates":74},[75,76],-84.38798,33.749,{"lat":76,"lon":75},[79,83],{"name":80,"role":42,"phone":81,"phoneExt":44,"email":82},"Suzanne Corley","404-605-3118","suzanne.corley@piedmont.org",{"name":84,"role":67,"phone":44,"phoneExt":44,"email":44},"Venkateshwar Polsani, MD",{"facility":86,"status":49,"city":87,"state":88,"zip":89,"country":53,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Beth Israel Deaconess Medical Center","Boston","Massachusetts","02215",{"type":55,"coordinates":91},[92,93],-71.05977,42.35843,{"lat":93,"lon":92},[96,99,102],{"name":97,"role":42,"phone":44,"phoneExt":44,"email":98},"Constance Angell-James, MPH","cangellj@bidmc.harvard.edu",{"name":100,"role":42,"phone":44,"phoneExt":44,"email":101},"Madeline Cassidy","mcassid6@bidmc.harvard.edu",{"name":103,"role":67,"phone":44,"phoneExt":44,"email":44},"Jordan Strom, MD",{"facility":105,"status":106,"city":107,"state":108,"zip":109,"country":53,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Oregon Health and Sciences University","NOT_YET_RECRUITING","Portland","Oregon","97239",{"type":55,"coordinates":111},[112,113],-122.67621,45.52345,{"lat":113,"lon":112},[116,120,122],{"name":117,"role":42,"phone":118,"phoneExt":44,"email":119},"Amy Koski","503-360-6705","koskia@ohsu.edu",{"name":121,"role":67,"phone":44,"phoneExt":44,"email":44},"David German, MD",{"name":123,"role":124,"phone":44,"phoneExt":44,"email":44},"Brian Davidson, MD","SUB_INVESTIGATOR",{"facility":126,"status":127,"city":128,"state":129,"zip":130,"country":53,"cosmosGeoPoint":131,"geoPoint":135,"contacts":44},"University of Texas Medical Branch","WITHDRAWN","Galveston","Texas","77555",{"type":55,"coordinates":132},[133,134],-94.7977,29.30135,{"lat":134,"lon":133},{"facility":137,"status":49,"city":138,"state":129,"zip":139,"country":53,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Vital Heart and Vein","Humble","77338",{"type":55,"coordinates":141},[142,143],-95.26216,29.99883,{"lat":143,"lon":142},[146,150],{"name":147,"role":42,"phone":148,"phoneExt":44,"email":149},"Ovee Muhebb","281-572-0109","s.muhebb@vitalheartandvein.com",{"name":151,"role":67,"phone":44,"phoneExt":44,"email":44},"Patrick Kee, MD",{"type":153,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100546825",false,"NCT06400004","Lumason® Infusion vs. Bolus Administrations","A Phase III Crossover Study to Evaluate Bolus Versus Continuous Infusion of Lumason® in Patients With Suboptimal Unenhanced Echocardiography","Inclusion Criteria:\n\n* Are at least 18-years old;\n* Have suboptimal LV EBD, defined as ≥2 adjacent segments in any apical view that cannot be visualized, at pre-contrast echocardiogram;\n* Provide their written informed consent and are willing to comply with protocol requirements.\n\nExclusion Criteria:\n\n* Patient has severe congestive heart failure (class IV according to the classification of the New York Heart Association);\n* Patient has uncontrolled angina (i.e., uncontrolled on medication);\n* Patient had a recent myocardial infarction (within the last 3 days and not stabilized);\n* Patient has severe arrhythmia, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient has severe pulmonary hypertension, that in the opinion of the Investigator, would interfere with the study conduct;\n* Patient had been treated with any other contrast medium, either intravascular or orally, within 48 hours prior to the first administration;\n* Has any known allergy to one or more of the ingredients of the investigational product;\n* Is pregnant or lactating. Exclude the possibility of pregnancy by: testing on site (serum or urine βHCG) prior to the start of investigational product administration; surgical history (e.g., tubal ligation or hysterectomy); post-menopausal with a minimum 1 year without menses;\n* Has previously entered the study or have received any other investigational drug within 30 days prior to admission in this study;\n* Is determined by the Investigator that the patient is clinically unsuitable for the study.","ALL","18 Years",{"count":163,"type":164},106,"ESTIMATED","INTERVENTIONAL",[167],"PHASE3","A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary endpoints).",[170],"Heart Diseases","2026-03-04",{"date":173,"type":174},"2026-03-05","ACTUAL",{"date":176,"type":174},"2024-07-10",{"date":178,"type":164},"2026-12-31",{"name":5,"class":6},6]